Skip To Main Content

Frequently Asked Questions

An EUA is a US Food and Drug Administration (FDA) authorization for the emergency use of an unapproved product or unapproved use of an approved product (ie, drug, biological product, or device) in the United States under certain circumstances including, but not limited to, when the Secretary of HHS declares that there is a public health emergency that affects the national security or the health and security of United States citizens living abroad, and that involves biological agent(s) or a disease or condition that may be attributable to such agent(s). Criteria for issuing an EUA include 1:

  • The biological agent(s) can cause a serious or life-threatening disease or condition;
  • Based on the totality of the available scientific evidence (including data from adequate and well-controlled clinical trials, if available), it is reasonable to believe that the product may be effective in diagnosing, treating, or preventing the serious or life-threatening disease or condition;
  • The known and potential benefits of the product—when used to diagnose, prevent, or treat such disease or condition—outweigh the known and potential risks of the product, taking into consideration the material threat posed by the biological agent(s); and
  • There is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating the serious or life-threatening disease or condition. For information on clinical studies of ACTEMRA and other therapies for the treatment of COVID-19, see

The EUA process differs from the FDA-approval process in that an EUA makes a product available for use in an emergency based on the best currently available data, without waiting for the additional evidence that would be required for an FDA approval. EUAs are in place for the duration of the declaration that circumstances exist justifying the authorization of the emergency use. They may be revised or revoked as the FDA continues to evaluate patient needs and the data available. 1,2

Under the EUA, ACTEMRA is authorized for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adults and pediatric patients (2 years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). However, ACTEMRA is not FDA-approved for this use.

ACTEMRA is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of ACTEMRA under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. See the full Fact Sheet for Healthcare Professionals  for the justification for emergency use of drugs during the COVID-19 pandemic, information on available alternatives, and additional information on COVID-19. 1

The adverse reaction rates observed in the clinical studies of ACTEMRA used to support this EUA cannot be directly compared to rates in the clinical studies of ACTEMRA for FDA-approved indications and may not reflect the rates observed in clinical practice.

The safety evaluation of ACTEMRA in COVID-19 was based on 4 clinical trials. These included one randomized, controlled, open-label, platform trial [Randomised Evaluation of COVID-19 Therapy (RECOVERY)] and 3 randomized, double-blind, placebo controlled trials (EMPACTA, COVACTA, and REMDACTA). For more information on the safety findings from the EUA clinical trials, please see the Safety Data page and the Fact Sheet for Healthcare Professionals . 1

ACTEMRA subcutaneous (SC) administration is not authorized for the treatment of COVID-19 patients. 1

The prescribing healthcare provider and/or the provider’s designee are/is responsible for mandatory reporting of all serious adverse events* and medication errors potentially related to ACTEMRA within 7 calendar days from the onset of the event, using FDA Form 3500 (for information on how to access this form, see below). The FDA recommends that such reports, using FDA Form 3500, include the following 1:

  • Patient demographics and baseline characteristics (eg, patient identifier, age or date of birth, gender, weight, ethnicity, and race)
  • A statement "ACTEMRA use for COVID-19 under Emergency Use Authorization (EUA)” under the “Describe Event, Problem, or Product Use/Medication Error” heading
  • Information about the serious adverse event or medication error (eg, signs and symptoms, test/laboratory data, complications, timing of drug initiation in relation to the occurrence of the event, duration of the event, treatments required to mitigate the event, evidence of event improvement/disappearance after stopping or reducing the dosage, evidence of event reappearance after reintroduction, clinical outcomes)
  • Patient’s preexisting medical conditions and use of concomitant products
  • Information about the product (eg, dosage, route of administration, NDC #)

Submit adverse event and medication error reports, using Form 3500, to FDA MedWatch using one of the following methods 1:

  • Complete and submit the report online:
  • Complete and submit a postage-paid FDA Form 3500 ( and return by:
    • Mail to MedWatch, 5600 Fishers Lane, Rockville, MD 20852-9787, or
    • Fax to 1-800-FDA-0178
  • Call 1-800-FDA-1088 to request a reporting form
    In addition, please provide a copy of all FDA MedWatch forms to:
    Genentech US Drug Safety
    Fax: 1-650-238-6067 or 1-650-225-4630
    E-mail: [email protected] or call Genentech at 1-888-835-2555 to report adverse events

The prescribing health care provider and/or the provider’s designee is/are to provide mandatory responses to requests from FDA for information about adverse events and medication errors associated with ACTEMRA. 1

*Serious adverse events are defined as:

  • Death or a life-threatening adverse event;
  • A medical or surgical intervention to prevent death, a life-threatening event, hospitalization, disability, or congenital anomaly;
  • Inpatient hospitalization or prolongation of existing hospitalization;
  • A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; or
  • A congenital anomaly/birth defect

For more information about the clinical profile for ACTEMRA in COVID-19, please contact your local Medical Service Liaison. Additionally, you may contact Genentech Medical Affairs or call 1-800-821-8590.

ACTPen is a registered trademark of Chugai Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group.


ACTEMRA is authorized for use under an Emergency Use Authorization (EUA) for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adults and pediatric patients (2 years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

ACTEMRA is not FDA-approved for this use.

ACTEMRA is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of ACTEMRA under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.



ACTEMRA is contraindicated in patients with known hypersensitivity to ACTEMRA.


Serious Infections

In COVID-19 patients, ACTEMRA should not be administered if patients have any other concurrent active infection, including localized infection.

Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, protozoal, or other opportunistic pathogens have been reported in patients receiving immunosuppressive agents including ACTEMRA. The most common serious infections included pneumonia, urinary tract infection, cellulitis, herpes zoster, gastroenteritis, diverticulitis, sepsis, and bacterial arthritis. Among opportunistic infections, tuberculosis, cryptococcus, aspergillosis, candidiasis, and pneumocystosis were reported with ACTEMRA. Other serious infections, not reported in clinical studies, may also occur (e.g., histoplasmosis, coccidioidomycosis, listeriosis).

The risks and benefits of treatment should be considered prior to initiating ACTEMRA in patients with chronic or recurrent infection, or who have a history of a serious or an opportunistic infection.

Closely monitor patients for the development of signs and symptoms of infection during and after treatment with ACTEMRA, as signs and symptoms of acute inflammation may be lessened due to suppression of the acute phase reactants.

A patient who develops a new infection during treatment with ACTEMRA should undergo a prompt and complete diagnostic workup appropriate for an immunocompromised patient; initiate appropriate antimicrobial therapy, and closely monitor the patient.

Gastrointestinal Perforations

Events of gastrointestinal perforation have been reported in clinical trials for chronic indications, primarily as complications of diverticulitis, in patients treated with ACTEMRA. Use ACTEMRA with caution in patients who may be at increased risk for gastrointestinal perforation. Promptly evaluate patients presenting with new onset abdominal symptoms for early identification of gastrointestinal perforation.


Patients hospitalized with COVID-19 may have elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels. Multi-organ failure with involvement of the liver is recognized as a complication of severe COVID-19.

During randomized, controlled studies, treatment with ACTEMRA was associated with a higher incidence of transaminase elevations. Serious cases of hepatic injury have been observed in patients taking intravenous or subcutaneous ACTEMRA chronically. In this setting, the time to onset for cases ranged from months to years after treatment initiation with ACTEMRA.

The decision to administer ACTEMRA should balance the potential benefit against the risks of acute treatment with ACTEMRA. ACTEMRA is not recommended in COVID-19 patients with elevated ALT or AST above 10 times the upper limit of the reference range. When ACTEMRA is used for treatment of COVID-19, ALT and AST should be monitored according to current standard clinical practice.

Laboratory Parameters

In randomized, controlled trials, patients receiving ACTEMRA had higher rates of neutropenia, thrombocytopenia, and elevations of ALT or AST.

ACTEMRA is not recommended in COVID-19 patients with an absolute neutrophil count (ANC) less than 1000 per mm3, platelet count below 50,000 per mm3, or ALT or AST above 10 times the upper limit of the reference range. Monitor ALT, AST, neutrophils, and platelet counts according to current standard clinical practice.

Hypersensitivity Reactions, Including Anaphylaxis

Hypersensitivity reactions, including anaphylaxis, have been reported in association with ACTEMRA and anaphylactic events with a fatal outcome have been reported with intravenous infusion of ACTEMRA. These events have occurred both with and without previous hypersensitivity reactions and as early as the first infusion of ACTEMRA. ACTEMRA for intravenous use should only be infused by a healthcare professional with appropriate medical support to manage anaphylaxis. If anaphylaxis or other hypersensitivity reaction occurs, stop administration of ACTEMRA immediately and discontinue ACTEMRA permanently. Do not administer ACTEMRA to patients with known hypersensitivity to ACTEMRA.

Demyelinating Disorders

The impact of treatment with ACTEMRA on demyelinating disorders is not known, but multiple sclerosis and chronic inflammatory demyelinating polyneuropathy were reported rarely in rheumatoid arthritis clinical studies. Monitor patients for signs and symptoms potentially indicative of demyelinating disorders. Prescribers should exercise caution in considering the use of ACTEMRA in patients with preexisting or recent onset demyelinating disorders.

Active Hepatic Disease and Hepatic Impairment

ACTEMRA is not recommended in patients with active hepatic disease or hepatic impairment.


Avoid use of live vaccines concurrently with ACTEMRA as clinical safety has not been established. The interval between live vaccinations and initiation of ACTEMRA therapy should be in accordance with current vaccination guidelines regarding immunosuppressive agents.

No data are available on the secondary transmission of infection from persons receiving live vaccines to patients receiving ACTEMRA.

No data are available on the effectiveness of vaccination in patients receiving ACTEMRA.


Most common adverse reactions (incidence ≥3%) are constipation, anxiety, diarrhea, insomnia, hypertension, and nausea.


Inhibition of IL-6 may lead to increased metabolism of drugs that are CYP450 substrates. Caution should be exercised when co-administering ACTEMRA with CYP3A4 substrate drugs where decrease in effectiveness is undesirable. The effect of ACTEMRA on CYP450 enzyme activity may persist for several weeks after stopping therapy.



There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ACTEMRA during pregnancy. Healthcare providers are encouraged to register patients and pregnant women are encouraged to register themselves by calling 1-877-311-8972.

The limited available data with ACTEMRA in pregnant women are not sufficient to determine whether there is a drug-associated risk for major birth defects and miscarriage. ACTEMRA should be used during pregnancy only if the potential benefit justifies the potential risk for the mother and the fetus.


No information is available on the presence of tocilizumab in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. Breastfeeding individuals with COVID-19 should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.

You or your designee must report all SERIOUS ADVERSE EVENTS or MEDICATION ERRORS potentially related to ACTEMRA (1) by submitting FDA Form 3500 online, (2) by downloading this form and then submitting by mail or fax, or (3) contacting the FDA at 1-800-FDA-1088 to request this form. Please also provide a copy of this form to Genentech at [email protected] or call 1-888-835-2555.

Please see additional information in Fact Sheet for Healthcare Providers Fact Sheet for Patients and Parents/Caregivers , and FDA Letter of Authorization .

Please see additional Important Safety Information in full Prescribing Information , including BOXED WARNING and other risks associated with chronic use of ACTEMRA.

As a healthcare practitioner, you must communicate to the patient and/or caregiver information consistent with the Fact Sheet for Patients and Parents/Caregivers  and provide them with a copy of this Fact Sheet prior to administration of ACTEMRA. However, if providing this information will delay the administration of ACTEMRA to a degree that would endanger the life of a patient, the information must be provided to the parent and/or caregiver as soon as feasible after ACTEMRA administration.